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There is a well known association between end stage renal disease and the development
of kidney cancer in the native kidney of patients requiring renal replacement therapy.There
is now emerging evidence that lesser degrees of renal insufﬁciency (chronic kidney dis-
ease, CKD) are also associated with an increased likelihood of cancer in general and kidney
cancer in particular. Nephropathological changes are commonly observed in the non-tumor
bearing portions of kidney resected at the time of partial and radical nephrectomy (RN). In
addition, patients with renal cancer are more likely to have CKD at the time of diagnosis
and treatment than the general population. The exact mechanism by which renal insufﬁ-
ciency transforms normal kidney cells into tumor cells is not known. Possible mechanisms
include uremic immune inhibition or increased exposure to circulating toxins not adequately
cleared by the kidneys. Surgeons managing kidney tumors must have an increased aware-
ness of their patient’s renal functional status as they plan their resection. Kidney sparing
approaches, including partial nephrectomy (PN) or active surveillance in older and morbidly
ill patients, can prevent CKD or delay the further decline in renal function which is well
documented with RN. Despite emerging evidence that PN provides equivalent local tumor
control to RN while at the same time preventing CKD, this operation remains under utilized
in the United States and abroad. Increased awareness of the bi directional relationship
between kidney function and kidney cancer is essential in the contemporary management
of kidney cancer.
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INTRODUCTION
It is well known that end stage renal disease (ESRD) patients
requiring renal replacement therapy either by dialysis or trans-
plantation are at increased risk for developing cancer and at four
to ﬁvefold increased risk of developing renal cancer in their native
kidneys (Birkelan et al., 2000; Buell et al., 2005; Mandayam and
Shahinian, 2008). Mortality related to ESRD related kidney cancer
depends upon the variable metastatic potentials of the tumor and
competing threats posed by complex cardiovascular and medical
diseaseswhich result fromor cause of the kidney disease. Emerging
evidence now exists which also associates chronic kidney disease
(CKD) with a greater risk of cancer and kidney cancer in particu-
lar.Diffuse nephropathological changes are commonly observed in
the non-neoplastic kidney at the time of nephrectomy for cancer.
These histopathological ﬁndings correlate with a greater baseline
risk of CKD in the kidney patient than the population at large.
It is not currently known whether the underlying damage to the
kidney is a carcinogenic event in and of itself or whether renal
dysfunction allows for carcinogenic toxins or immune inhibition
that then transforms normal kidney cells into cancer cells.
For surgeons planning operations on patients with renal
tumors, oncological goals of providing local tumor control by
radical or partial nephrectomy (PN) must now be tempered by
an understanding of the baseline renal functional health of the
patient and the potential impact of operation on overall renal
function. There is now abundant clinical evidence which suggests
radical nephrectomy (RN) for small renal masses is over treatment
fromanoncological perspective and causes orworsenspre-existing
CKD. Knowledge of this bi directional relationship between kid-
ney function and kidney cancer is an essential component in the
management of kidney tumor patients.
THE PROBLEM OF KIDNEY CANCER
An estimated 60,920 new cases and 13,120 deaths from kidney
cancer occurred in the United States in 2011. Kidney cancer is
increasing at a rate of approximately 3% per year. Compared with
1971, this represents a ﬁvefold increase in incidence and twofold
increase in mortality. Associated risk factors include hypertension,
smoking, obesity, and diabetes. Epidemiologic evidence suggests
an increase in all stages of renal cancer including the advanced
and metastatic cases (McLaughlin and Lipworth, 2000; Ljungberg
et al., 2011). Approximately 30–40% of renal tumor patients will
either present with or later develop metastatic disease. The wide-
spread use of the modern abdominal imaging techniques (CT,
MRI, and ultrasound) over the last 20 years, usually ordered to
evaluate non-speciﬁc abdominal and musculoskeletal complaints
or during unrelated cancer care, has changed the proﬁle of the
typical renal tumor patient from one with a massive, symptomatic
tumor at presentation to one with a small, asymptomatic, renal
mass (<4 cm) incidentally discovered in 70% of the cases (Russo,
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2000).Over the last four decades, evidence from the SEERdatabase
suggests an increase in the incidence of kidney cancer in blacks, an
American population less likely to have access to incidental tumor
detection and exposed to lesser rates of nephrectomy but more
likely to have unrecognized and untreated hypertension, diabetes,
and CKD. Despite this, mortality rates in blacks are equivalent to
whites raising the possibility that kidney cancer is less aggressive
in black patients (Lipworth et al., 2011).
Despite this size and stagemigration,kidney cancer speciﬁc sur-
vival rates have not signiﬁcantly improved over the last 15 years.
This disconnect suggests that aggressive treatment of smaller
tumors is not sufﬁcient to offset more virulent disease seen in
all stages in general or advanced stages in particular (Russo et al.,
2008). A survival rate of 90% or greater, depending on the tumor
histology, is expected for small tumors whether PN or RN is per-
formed (Kattan et al., 2001; Russo, 2010). We now understand
that renal cortical tumors are members of a complex family with
unique histopathology, cytogenetics, familial and hereditary syn-
dromes, and variable metastatic potentials. Approximately 20%
of patients with surgically resected renal masses will be a benign
lesion (i.e., angiomyolipoma,oncocytoma,metanephric adenoma,
or hemorrhagic cyst), 25% will be an indolent tumor (papillary,
chromophobe carcinoma) with limited metastatic potential, and
54% will be the more potentially malignant conventional clear-cell
carcinoma that accounts for 90% of the metastatic renal tumors
(Teloken et al., 2009; Algaba et al., 2011).
END STAGE RENAL DISEASE: ASSOCIATION WITH CANCER
AND KIDNEY CANCER
A deﬁnite association between malignancy and ESRD has been
reported (Matas et al., 1975; Cengiz, 2002). Stewart evaluated
28,855 patients who required renal replacement therapy and
reported a fourfold increased incidence of cancer. Immune deﬁ-
ciency related cancers were increased from 1.5-fold while on
dialysis to ﬁvefold after transplantation and the initiation of anti-
rejection medication. The authors speculated that this increase
after transplantation could be virally mediated (Stewart et al.,
2009). Liang matched 21,817 ESRD patients in Taiwan to patients
from the general population without ESRD and found the risk of
developing cancer was 64% higher in the ESRD patients (Liang
et al., 2011). Lee evaluated 4582 patients with ESRD and found
106 patients that developed cancer. The most common cancers
were from the GI tract (51%), urinary tract (20%), and lung (8%).
In this sub group of patients, 69% of the mortality was due to can-
cer (Lee et al., 2009). Mosconi et al. (2011) evaluated 1184 Italian
patients with ESRD on a kidney transplant waiting list and found
cancers in 2.2% of patients, most of which were non-metastatic
with the most common arising from kidney and thyroid.
It has also been reported that ESRD patients have a higher
prevalence of renal cell carcinoma than the general populations
(Ishikawa and Kovacs, 1993) and distinct clinical and pathological
features can be identiﬁed in ESRD patients. Neuzillet compared
the pathological features of 303 renal cancer patients with ESRD
to 947 sporadic renal cancer patients and found that the mean
age at diagnosis was younger (55 v 62), the mean tumor size was
smaller (3.7 vs. 7.3 cm), more were asymptomatic (87 vs. 44%),
less were high stage (10 vs. 42%), less had nodal metastasis (3 vs.
12%) and less had distant metastasis (2 vs. 15%). After a median
follow up of 33months, 13 ESRD (4.3%) patients had died of renal
cancer vs. 261 (27.6%) from the sporadic tumor population. The
authors concluded that RCC arising in the native kidneys of ESRD
patientsmay have amore indolent natural history (Neuzillett et al.,
2011). Hora described pathological characteristics of renal cortical
tumors in 13ESRDpatients,which included 6bilateral procedures,
for a total of 19 kidney specimens. In 13 kidneys the tumors were
multiple and in 6 solitary. Papillary and clear-cell tumors alone or
in combination were reported (Hora et al., 2008). Hajj reported
89 nephrectomies (including 10 bilateral) resected in 79 patients
with autosomal dominant polycystic disease (ADPKD), 50 of who
had ESRD. In 11 of the 89 kidneys resected, renal cancer was found
including 1 bilateral and 3 multifocal tumor. Of these, 58.3% were
clear cell and 41.7% tubulopapillary carcinomas. The authors cal-
culated that the prevalence of renal cancer in the combination of
ADPKD and ESRD was two to three times more than in ESRD
patients alone (Hajj et al., 2009).
Nouth reported a wide spectrum of tumor histology distinct
from sporadic RCC in 34 ESRD patients that underwent RN for
renal cancer. Pathologic sub types included acquired cystic dis-
ease (ACD) associated RCC, mucinous tubular, spindle cell, and
Xp11.2 translocation renal cell carcinoma. In 9/15 patients with
a duration of dialysis less than 10 years, conventional clear cell
was the predominant histology whereas ACD associated RCC was
predominant (7/12) in those with dialysis of greater than 10 years
(Nouth et al., 2009). Suson reported 15 post transplant patients
who underwent nephrectomy for renal masses in their native kid-
ney. A total of 22 renal units were removed and a total of 18
cancers, 10 of which were P1, were resected. There were 11 papil-
lary, 4 clear cell, and 3 chromophobe cancers. Only one patient in
this experience developed metastatic disease (Suson et al., 2011).
These reports, when taken together, describe a propensity for the
development of a wide range of renal cortical cancers in patients
with ESRDwhose renal tumors as a wholemay have lessmetastatic
potential than sporadic renal cancers.
CHRONIC KIDNEY DISEASE: PREVALENT, SERIOUS, AND
UNDERAPPRECIATED DISEASE
Chronic kidney disease, deﬁned as an estimated glomerular ﬁltra-
tion rate (eGFR) of less than 60ml/min/1.73m2, is increasingly
viewed as a major public health problem in the United States and
since 2003 is considered an independent cardiovascular risk fac-
tor (Kidney Disease Outcome Quality Initiative, 2002; Chobanian
et al., 2003; Sarnak et al., 2003; Ritz and McClellan, 2004; Shlipak
et al., 2005). The prevalence of CKD in the general population is
4% but may be as high as 30% in the elderly population. An esti-
mated 19 million adults in the United States have CKD and by the
year 2030, 2 million of these will progress to ESRD and be in need
of chronic dialysis or renal transplantation (Coresh et al., 2007).
Worldwide epidemics of cardiovascular disease, obesity, hyper-
tension, and diabetes, all of which can have adverse effects on
the kidney, have gained increasing attention but their contribu-
tion to the development of CKD has gone relatively unnoticed
amongst clinicians and patients alike. The adverse impact of CKD
on cardiovascular disease is signiﬁcant as CKDprogresses to ESRD
(Stenvinkel, 2010). A study by Go involving 1,120,295 patients
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demonstrated a direct correlation between the stages of CKD and
rates of hospitalization, cardiovascular events, and death, which
occurred before overt ESRD requiring dialysis or renal trans-
plantation (Go et al., 2004). As kidney function deteriorated, the
percentage of patients with two associated cardiovascular risk fac-
tors increased from 34.7% (Stage 1 and 2 CKD) to 83.6% (for stage
3) to 100% for stage 4 and 5 subjects. Patients with CKD are more
likely to require medical interventions to treat cardiovascular dis-
ease than those with normal renal function. The low prevalence of
patients with Stage 4 or 5 CKD is attributable to a 5-year survival
rate of only 30% (Foley et al., 2005).
The adverse impact of CKD increases as the patient popula-
tion at risk ages. Stevens explored the prevalence and impact of
CKD in patients over 65 in the USA in a large combined data
set which included NHANES, KEEP, and a 5% sample of Medicare
(n= 1,236,946) and found that as the eGFRdecreased, the comor-
bid metabolic conditions of anemia, hypocalcemia, hyperphos-
phatemia, and hyperparathyroidism increased. The subsequent
impact of these conditions on overall health has made CKD a crit-
ical disease in need of increased awareness by the entire medical
community (Stevens et al., 2010). This high prevalence of CKD in
the aging and elderly effects is superimposed upon the very same
patient population most at risk for the development of cancer.
CKD: ASSOCIATIONS WITH CANCER AND KIDNEY CANCER
As with ESRD, there are now reports indicating that patients with
CKD are at higher risk for the development of cancer in addition
to cardiovascular disease. Weng evaluated 123,717 adults in Tai-
wan in 1998 and calculated their eGFR. After a median of over
7 years, mortality was ascertained by computer linkage to their
national death registry. The investigators found a higher overall
cancer mortality in CKD patients vs. non-CKD patients. CKD
was associated with an adjusted hazard ratio of 1.74, 3.3, and 7.3
for liver, kidney, and urothelial cancers respectively (Weng et al.,
2011). Wong evaluated 3654 patients in Australia aged 49–97 and
followed them for a mean 10.1 years. Cancer developed in 711
patients (19.5%). Men with CKD 3 were at increased risk for the
development of cancer starting at an eGFR of 55 (HR 1.39). For
every 10ml/min decrement decline in eGFR, the risk of cancer
rose 29% and was at greatest risk for an eGFR of 40 (HR 3.01)
with lung and urinary tract the most likely diagnoses (Wong et al.,
2009).
Cancer patients appear to have a higher rate of CKD than the
general population. Launay-Vacker et al. (2007) evaluated 4684
patients with cancer, median age 58, and reported that 12 and
20% had an eGFR less than 60ml/min/1.73m2 by the modiﬁ-
cation in diet and renal disease (MDRD) and Cockcroft Gault
equations respectively. Canter reported the prevalence of base-
line CKD in 1114 patients presenting with solid renal tumors.
Twenty-two percent had stage 3 CKD or greater despite 88%
having a serum creatinine within normal limits (<1.4mg/dl).
In a sub group of 282 patients 70 years or older, 113 (40%)
had CKD stage 3 (Huang et al., 2006). These results are similar
to those ﬁrst reported by MSKCC investigators which demon-
strated a 26% rate of CKD in 662 patients with small renal
tumors and a serum creatinine within normal limits (Huang et al.,
2006).
CANCER AND KIDNEY CANCER ASSOCIATED
NEPHROPATHOLOGY
The extent to which ESRD, CKD associated nephropathological
changes are simply associated with kidney tumors or cause kid-
ney tumors is not known and is of great current interest amongst
urological oncologists, nephrologists, and pathologists alike. In
patients with ESRD,numerous renal cysts develop and persistently
grow in native kidneys even after transplantation. Goh reported
10 asymptomatic transplant recipients who developed renal cell
carcinoma in native kidneys at a median of 5.8 years while their
grafts were functioning at greater than 90% rate. The patients
at greatest risk for developing renal cancer were those with pre-
existing renal cysts and those on dialysis the longest (Goh and
Vathsala, 2011). In patients without ESRD/CKD and renal can-
cer, many nephropathological changes are observed. Bijol from
Harvard Medical School examined the non-tumor bearing nor-
mal appearing kidney in 110 nephrectomy specimens resected for
kidney cancer. Extensive and unsuspected underlying renal dis-
ease including vascular sclerosis, diabetic nephropathy, glomerular
hypertrophy, mesangial expansion, and diffuse glomerulosclero-
sis was reported. Only 10% of patients had completely normal
renal tissue adjacent to the tumor (Bijol et al., 2006). Henriksen
et al. (2009) conﬁrmed a wide range of kidney abnormalities in
the non-neoplastic kidney, including mesangial sclerosis or hyper-
cellularity, segmental sclerosis, crescent formation, glomerulitis,
and glomerular basementmembrane disease. Pathologists are now
being urged to routinely report these ﬁndings in routine tumor
nephrectomy specimens (Bonsib and Pei, 2010).
The precise mechanisms by which the uremic state, dialysis,
and transplantation causes malignant transformation in the kid-
ney are unknown and are likely multi-factorial. Cancer induced
paraneoplastic nephropathy, exposure to toxins, viral mediated
carcinogenesis, immune inhibition, and circulating toxins have
all been implicated in the process of increased cancer in patients
with ESRD/CKD (Stengel, 2010). Retention of uremic toxins,
such as p-cresol, could promote malignant transformation by
their inhibitory effect on the immune system and transendothelial
leukocyte migration (Dou et al., 2002; Faure et al., 2006). Future
research is required to deﬁne the precise mechanism by which
uremic conditions predispose patients to cancer.
RENAL TUMOR SURGERY AND NEW CONCERNS FOR CKD
After World War 2, improvements in surgical technique and peri-
operative care allowed for the radical resection of massive renal
tumors (RN) with results indicating excellent local tumor con-
trol and long term survival in greater than 50% of patients in
the absence of metastatic or regional nodal disease (Russo, 2006,
2011). However, a historic misconception was propagated that
implied that the loss of a kidney to cancer surgery and the subse-
quent and expected rise in serum creatinine would have minimal
if any impact of the patient’s health as long as there was a normal
contra lateral kidney. The renal transplant literature was cited as
the clinical evidence to support this view since patients undergo-
ing donor nephrectomy were reported not to have higher rates
of kidney failure requiring dialysis or death (Segev et al., 2010).
However, distinct differences between kidney donors and kidney
tumor patients exist. Donors were carefully screened for medical
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co-morbidities and are generally young (age 45 or less; Fehrman-
Ekholm et al., 2001; Goldfarb et al., 2001). In contrast, renal tumor
patients are not screened, are older (mean age 61 years), and many
have signiﬁcant co-morbidities affecting baseline kidney func-
tion includingmetabolic syndrome,hypertension, coronary artery
disease, obesity, vascular disease, and diabetes. In addition, as
patient’s age, particularly beyond 60 years, nephrons atrophy and
glomerular ﬁltration rate progressively decreases (Kaplan et al.,
1975).
Evidence that RN could cause a signiﬁcant rise in the serum
creatinine when compared to PN in patients with renal corti-
cal tumors of 4 cm or less was published by investigators from
Mayo Clinic and MSKCC in 2000 and 2002, respectively. RN
patients were more likely to have elevated serum creatinine lev-
els to >2.0 ng/ml and proteinuria (Mayo Study; Lau et al., 2000),
a persistent ﬁnding even when study patients were carefully
matched for associated risk factors (MSKCC study) including dia-
betes, smoking history, pre-operative serum creatinine, and ASA
score (McKiernan et al., 2002). In both studies, oncological out-
comes were highly favorable (>90% survival rates) whether PN
or RN was performed. A new and emerging concern that the
overzealous use of RN, particularly in elderly patients with small
renal masses and common co-morbidities that can affect renal
function, could be cause or worsen pre-existing CKD became a
focus of intensive research. MSKCC investigators used a widely
available formula, the MDRD equation (Stevens et al., 2006;
http://www.nephron.com/MDRD_GFR.cgi), to eGFR in a retro-
spective cohort study of 662 patients with a normal serum creati-
nine and2healthy kidneys that underwent either electivePNorRN
for a RCT 4 cm or less in diameter. To their surprise, 171 patients
(26%) had pre-existing CKD (GFR<60). Data was analyzed using
two threshold deﬁnitions of CKD, a GFR <60ml/min/1.73m2 or
a GFR <45ml/min/1.73m2. After surgery, the 3-year probability
of freedom from new onset of GFR <60 was 80% after PN but
only 35% after RN. Corresponding values for 3 year probability
of freedom from a GFR <45, a more severe level of CKD, was
95% for PN and 64% for RN. Multivariable analysis indicated
that RN was an independent risk factor for the development of
new onset CKD (Huang et al., 2006). Mayo Clinic investigators
identiﬁed 648 patients from 1989 to 2003 treated with RN or PN
for a solitary renal tumor less than or equal to 4 cm with a nor-
mal contra lateral kidney. In 327 patients younger than 65 it was
found that RN was signiﬁcantly associated with an increased risk
of death which persisted after adjusting for year of surgery, dia-
betes, Charlson–Romano index, and tumor histology (Thompson
et al., 2008).
Using the Surveillance, Epidemiology, and End Results cancer
registry data linked with Medicare claims, MSKCC investigators
studied 2991 patients older than 65 years for resected renal tumors
of 4 cm or less from 1995 to 2002. A total of 254 patients (81%)
underwent RN and 556 patients underwent PN. During a median
follow up of 4 years, 609 patients experienced a cardiovascular
event and 892 patients died. After adjusting for pre-operative
demographic and co-morbidity variables, RN was associated with
a 1.38 times increased risk of overall mortality and a 1.4 times
greater number of cardiovascular events (Huang et al., 2009). Sim-
ilar results were reported in patients undergoing laparoscopic RN
and PN (Foyil et al., 2008). Because of these reports, urologists are
now increasingly aware that CKD can be caused or pre-existing
CKD signiﬁcantly worsened by the liberal use of RN for the treat-
ment of the small renal mass (Lane et al., 2009). Short term end
points, including length of hospital stay, analgesic requirements,
and cosmetic elements viewed by many as the reason to elect
laparoscopic RN, must now be tempered by the guaranteed renal
functional decline after RN. The most recent AUA guidelines for
the management of the small renal tumor emphasize these points
and strongly support the use of PN whenever technically feasible
(Campbell et al., 2009).
RADICAL NEPHRECTOMY IS OVER-UTILIZED
Despite the above well described oncological and medical argu-
ments in the contemporary literature supporting PN as the ideal
treatment for small renal masses, the urological oncology com-
munity continues to use RN as the predominant treatment of
the small renal mass. A cross sectional view of clinical practice
using the Nationwide Inpatient Sample, revealed that only 7.5%
of kidney tumor operations in the United States 1988–2002 were
PN (Hollenback et al., 2006). Using the surveillance epidemiology
and end results (SEER) data base, investigators from theUniversity
of Michigan reported that only 20% of all renal cortical tumors
between 2 and 4 cmwere treated by PN (Miller et al., 2006a). Using
the SEER data base linked to Medicare claims, MSKCC investiga-
tors reported a PN utilization rate of only 19% for T1a tumors
(4 cm or less; Huang et al., 2009). Interestingly and for uncer-
tain reasons, women and elderly patients are more likely to be
treated with RN (Dulabon et al., 2010). Many urologists believe
a “quick” RN in an elderly patient would expose the patient to
fewer post operative complications than would a PN. However,
MSKCC investigators evaluated age and type of procedure per-
formed in 1712 patients with kidney tumors found a lack of
statistical evidence that the risk of complications associated with
PN increased with advancing age. Furthermore, no evidence was
reported linking age to estimated blood loss or operative time.
Given the advantages of renal functional preservation, the authors
concluded that elderly patients should be perfectly eligible for PN
(Lowrance et al., 2010). As mentioned above, the elderly patients
have the highest rates of underlying CKD and are most vulnerable
to the adverse impact of RN.
Although the urology literature has a great many articles writ-
ten concerning the use of laparoscopic techniques to resect kid-
ney tumors, the penetrance of laparoscopic RN according to the
National Inpatient Sample from 1991 to 2003 was only 4.6% with
a peak incidence of 16% in 2003. This data indicates that the bulk
of “kidney wasting operations” are being done by traditional open
surgical approaches (Miller et al., 2006b). In England, a similar
under-utilization of PN was reported in 2002 with only 108 (4%)
PN out of 2671 nephrectomies performed (Nuttail et al., 2005).
Investigators at MSKCC tracked nephrectomy use in 1533 patients
between 2000 and 2007 excluding patients with bilateral tumors
and tumors in a solitary kidney and including only patients with
an eGFR of greater than 45ml/min/1.73m2. Overall 854 (56%)
patients underwent PN and 679 (44%) underwent RN. In the 820
patients with a renal tumor of 4 cm or less, the frequency of PN
increased from 69% in 2000 to 89% in 2007. In the 365 patients
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with a renal tumor from 4 to 7 cm, the frequency of PN increased
from 20% in 2000 to 60% in 2007. Despite a commitment to
kidney sparing operations during this time frame by the MSKCC
group, multivariate analysis indicated that PN was a signiﬁcantly
favored approach for males, younger patients, smaller tumors, and
open surgeons (Thompson et al., 2009).
CONCLUSION
A previously understood association between ESRD patient’s
native kidneys and the development of kidney cancer has been
extended now to include patients with CKD. CKD is an increasing
public health problem in the United States and now considered
an independent risk factor for the development of cardiovascular
morbidity and mortality. CKD is multi-factorial and may be due
to common medical conditions including hypertension, diabetes,
obesity and vascular disease. As the eGFR decreases, metabolic
complications increase with patients over the age of 65 years par-
ticularly susceptible. These aging patients also have the greatest
vulnerability to the development of cancer. Patients with cancer
in general and kidney cancer in particular may have concomitant
CKD rates as high as 40%. In the non-neoplastic kidney at the
time of nephrectomy, extensive nephropathological ﬁndings are
observed in the vast majority of patients. It is not clear if these
changes are a direct cause of renal neoplasia or a result of medical
co-morbidities that are prevalent in the kidney tumor patients.
The precise mechanism by which the uremic state causes malig-
nant transformation is not known but it is speculated that uremic
toxins, viral mediators, and immune inhibition could play a role
in the increased rate of kidney cancer seen in ESRD/CKD patients.
For surgeons operating on small renal tumors, it is now clear that
PN provides equivalent oncological results to RN while at the
same time maximally preserving renal function and preventing or
delaying the onset of CKD and its late cardiovascular morbidity
and mortality. Despite a decade of clinical evidence in support of
kidney preservation surgical techniques, RN remains overused in
the United States and abroad. Formal support for PN in the man-
agement of small renal masses has been made by major urological
surgical organizations. A working knowledge of the bi directional
relationship of CKD/ESRD and the surgical management of renal
tumors is now essential for all urological oncologists.
REFERENCES
Algaba, F., Akaza, H., López-Beltrán,
A., Martignoni, G., Moch, H., Mon-
tironi, R., and Reuter, V. (2011).
Current pathology keys of renal
cell carcinoma. Eur. Urol. 60,
634–643.
Bijol, V., Mendez, G. P., Hurwitz,
S., Rennke, H. G., and Nosé, V.
(2006). Evaluation of the nonneo-
plastic pathology in tumor nephrec-
tomy specimens: predicting the risk
of progressive renal failure. Am. J.
Surg. Pathol. 30, 575.
Birkelan, S. A., Lokkegaard, H., and
Storm, H. H. (2000). Cancer risk
in patients on dialysis and after
renal transplantation. Lancet 355,
1886–1887.
Bonsib, S. M., and Pei, Y. (2010).
The non-neoplastic kidney in tumor
nephrectomy specimens: what can it
show and what is important? Adv.
Anat. Pathol. 4, 235–250.
Buell, J. F., Gross, T. G., and Woo-
dle, E. S. (2005). Malignancy after
transplantation. Transplantation 80,
S254–S264.
Campbell, S. C., Novick, A. C., Bellde-
grun, A., Blute, M. L., Chow, G. K.,
Derweesh, I. H., Faraday, M. M.,
Kaouk, J. H., Leveille, R. J., Matin, S.
F., Russo, P., and Uzzo, R. G. (2009).
Guideline for management of the
clinical T1 renal mass. J. Urol. 182,
1271–1279.
Cengiz, K. (2002). Increased inci-
dence of neoplasia in chronic
renal failure (20 year experi-
ence). Int. Urol. Nephrol. 33,
121–126.
Chobanian, A. V., Bakris, G. L.,
Black, H. R., Green, L. A., Izzo,
J. L., Jones, D. W., Materson, B.
J., Oparil, S., Wright, J. T., Roc-
cella, E. J., and the National High
Blood Pressure Education Program
Coordinating Committee. (2003).
The Seventh Report of the Joint
National Committee on TN pre-
vention, detection, evaluation, and
treatment of high blood pressure:
the JNC 7 report. JAMA 289,
2560–2572.
Coresh, J., Selvin, E., Stevens, L. A.,
Manzi, J., Kusek, J.W., Eggers, P.,Van
Lente, F., and Levey, A. S. (2007).
Prevalence of chronic kidney dis-
ease in the United States. JAMA 298,
2038–2047.
Dou, L., Cerini, C., Brunet, P., Guil-
lanelli, C., Moal, V., Grau, G.,
De Smet, R., Vanholder, R., Sam-
pol, J., and Berland, Y. (2002). P-
cresol, a uremic toxin, decreases
endothelial cell response to inﬂam-
matory cytokines. Kidney Int. 62,
1999–2009.
Dulabon, L. M., Lowrance,W. T., Russo,
P., and Huang, W. C. (2010). Trends
in renal tumor surgery delivery
within theUnited States.Cancer 116,
2316–2321.
Faure, V., Cerini, C., Paul, P., Berland,
Y., Dignat-George, F., and Brunet, P.
(2006). The uremic solute p-cresol
decreases leukocyte transendothelial
migration in vitro. Int. Immunol. 10,
1453–1459.
Fehrman-Ekholm, I., Duner, F., Brink,
B., Tydén, G., and Elinder, C. G.
(2001). No evidence of accelerated
loss of kidney function in living kid-
ney donors: results from a cross sec-
tional follow up. Transplantation 72,
444–449.
Foley, R. N., Wang, C., and Collins, A.
J. (2005). Cardiovascular risk factor
proﬁles and kidney function stage
in the US general population: the
NHANES 3 study. Mayo Clin. Proc.
80, 1270–1277.
Foyil,K.V.,Ames,C.D., Ferguson,Weld,
K. J., Figenshau, R. S., Venkatesh, R.,
Yan, Y., Clayman, R. V., and Land-
man, J. (2008). Long-term changes
in creatinine clearance after laparo-
scopic renal surgery. J. Am. Coll.
Surg. 206, 511–515.
Go, A. S., Chertow, G. M., Fan, D.,
McCulloch, C. E., and Hsu, C. Y.
(2004). Chronic kidney disease and
the risks of death, cardiovascular
events, and hospitalization. N. Eng.
J. Med. 351, 1296.
Goh, A., and Vathsala, A. (2011).
Re: native renal cysts and dialysis
duration are risk factors for renal
cell carcinoma in renal transplant
recipients. Am. J. Transplant. 11,
86–92.
Goldfarb, D. A., Matin, S. F., Braun, W.
E., Schreiber, M. J., Mastroianni, B.,
Papajcik, D., Rolin, H. A., Flechner,
S., Goormastic, M., and Novick, A.
C. (2001). Renal outcome 25 years
after donor nephrectomy. J. Urol.
166, 2043.
Hajj, P., Ferlicot, S., Massoud, W.,
Awad, A., Hammoudi, Y., Carpen-
tier, B., Durrbach, A., Droupy, S.,
and Benoit, G. (2009). Prevalence of
renal cell carcinoma in patients with
autosomal dominant polycystic kid-
ney disease and chronic renal failure.
Urology 74, 631–634.
Henriksen, K. J., Meehan, S. M.,
and Chang, A. (2009). Non-
neoplastic kidney diseases in
adult tumor nephrectomy and
nephroureterectomy specimens:
common, harmful, yet underappre-
ciated. Arch. Pathol. Lab. Med. 133,
1012–1025.
Hollenback, B. K., Tash, D. A.,
Miller, D. C., Dunn, R. L., and
Wei, J. T. (2006). National uti-
lization trends of partial nephrec-
tomy for renal cell carcinoma: a
case of underutilization? Urology 67,
254–259.
Hora, M., Hes, O., Reischig, T., Urge,
T., Klecka, J., Ferda, J., Michal, M.,
and Eret, V. (2008). Tumors in end-
stage kidney. Transplant. Proc. 10,
3354–3358.
Huang, W. C., Elkin, E. B., Levey,
A. S., Jang, T. L., and Russo, P.
(2009). Partial nephrectomy ver-
sus radical nephrectomy in patients
with small renal tumors-is there
a difference in mortality and car-
diovascular outcomes. J. Urol. 181,
55–62.
Huang, W. C., Levey, A. S., Serio, A.
M., Snyder, M., Vickers, A. J., Raj,
G. V., Scardino, P. T., and Russo,
P. (2006). Chronic kidney disease
after nephrectomy in patients with
renal cortical tumors: a retrospec-
tive cohort study. Lancet Oncol. 7,
735–740.
Ishikawa, I., and Kovacs, G. (1993).
High incidence of papillary renal
cell tumors in patients on chronic
haemodialysis. Histopathology 22,
135–139.
Kaplan, C., Pasternack, B., Shah, H.,
and Gallo, G. (1975). Age-related
incidence of sclerotic glomeruli in
human kidneys. Am. J. Pathol. 80,
227.
www.frontiersin.org April 2012 | Volume 2 | Article 28 | 5
Russo Renal insufﬁciency and cancer
Kattan, M. W., Reuter, V., Motzer, R.
J., Katz, J., and Russo, P. (2001).
A postoperative prognostic nomo-
gram for renal cell. J. Urol. 166,
63–67.
KidneyDiseaseOutcomeQuality Initia-
tive. (2002). K/DOQI clinical guide-
line for chronic kidney disease eval-
uation, classiﬁcation, stratiﬁcation.
Am. J. Kidney Dis. 39 (Suppl. 2),
51:5246.
Lane, B. R., Poggio, E. D., Herts, B. R.,
Novick, A. C., and Campbell, S. C.
(2009). Renal function assessment
in the era of chronic kidney disease:
renewed emphasis on renal function
centered patient care. J. Urol. 182,
436–444.
Lau, W. K., Blute, M. L., Weaver,
A. L., Torres, V. E., and Zincke,
H. (2000). Matched compar-
ison of radical nephrectomy
vs. nephron-sparing surgery in
patients with unilateral renal cell
carcinoma and a normal contra
lateral kidney. Mayo Clin. Proc. 75,
1236–1242.
Launay-Vacker, V., Oudard, S., Janus,
N., Gligorov, J., Pourrat, X., Rixe,
O., Morere, J. F., Beuzeboc, P.,
Deray, G., and Renal Insufﬁciency
and Cancer Medications (IRMA)
Study Group. (2007). Prevalence
of renal insufﬁciency in cancer
patients and implications for anti
cancer drug management. The renal
insufﬁciency and anticancer med-
ications study (IRMA). Cancer 110,
1376–1384.
Lee, J. E., Han, S. H., Cho, B. C., Park,
J. T., Yoo, T. H., Kim, B. S., Park, H.
C., Kang, S. W., Lee, H. Y., Han, D.
S., Ha, S. K., and Choi, K. H. (2009).
Cancer in patients on chronic dialy-
sis. J. Korean Med. Sci. 24 (Suppl. 1),
S95–S101.
Liang, J. A., Sun, L. M., Yeh, J. J., Sung,
F. C., Chang, S. N., and Kao, C.
H. (2011). The association between
malignancy and end stage renal dis-
ease in Taiwan. Jpn. J. Clin. Oncol.
41, 752–757.
Lipworth, L., McLaughlin, J. K., Tarone,
R. E., and Blot, W. J. (2011). Renal
cancer paradox:higher incidencebut
not highermortality amongAfrican-
Americans. Eur. J. Cancer Prev. 20,
331–333.
Ljungberg, B., Campbell, S. C., Cho,
H. Y., Jacqmin, D., Lee, J. E.,
Weikert, S., and Kiemeney, L.
A. (2011). The epidemiology of
renal cell carcinoma. Eur. Urol. 60,
615–621.
Lowrance, W. T., Yee, D. S., Sav-
age, C., Cronin, A. M., O’Brien,
M. F., Donat, M., Vickers, A., and
Russo,P. (2010).Complications after
radical and partial nephrectomy as
a function of age. J. Urol. 183,
1725–1730.
Mandayam, S., and Shahinian, V. B.
(2008). Are chronic dialysis patients
at increased risk for cancer? J.
Nephrol. 21, 166–174.
Matas,A. J., Simmons,R. L.,Kjellstrand,
C. M., Buselmeier, T. J., and Naajar-
ian, J. S. (1975). Increased incidence
of malignancy during chronic renal
failure. Lancet 1, 883–886.
McKiernan, J., Simmons,R.,Katz, J., and
Russo, P. (2002). Natural history of
chronic renal insufﬁciency after par-
tial and radical nephrectomy. Urol-
ogy 59, 816–820.
McLaughlin, J. K., and Lipworth, L.
(2000). Epidemiologic aspects of
renal cell cancer. Semin. Oncol. 27,
115–123.
Miller, D. C., Hollingsworth, J. M.,
Hafez, K. S., Daignault, S., and
Hollenbeck, B. K. (2006a). Partial
nephrectomy for small renal masses.
An emerging quality of care con-
cern? J. Urol. 175, 853–857.
Miller, D. C., Taub, D. A., Dunn, R.
L., Wei, J. T., and Hollenbeck, B. K.
(2006b). Laparoscopy for renal cell
carcinoma: diffusion versus region-
alization? J. Urol. 176, 1102–1106.
Mosconi, G., Stalterii, L., Centofanti,
F., Capelli, I., Carretta, E., Persici,
E., Ubaldi, G., Battaglino, G., Rai-
mondi, C., Scolari, M. P., and Ste-
foni, S. (2011). Incidence o cancer
in kidney transplantationwaiting list
patients: a single center experience.
Transplant. Proc. 43, 1003–1005.
Neuzillett, Y., Mathieu, R., Long, J.
A., Gigante, M., Paparel, P., Pois-
sonnier, L., Baumert, H., Escudier,
B., Lang, H., Rioux-Leclercq, N.,
Bigot, P., Bernhard, J. C., Albiges,
L., Bastien, L., Petit, J., Saint, F.,
Bruyere, F., Boutin, J. M., Brichart,
N., Karam, G., Branchereau, J., Fer-
riere, J. M., Wallerand, H., Barbet,
S., Elkentaoui,H.,Hubert, J., Feuillu,
B., Theveniaud, P. E., Villers, A.,
Zini, L., Descazeaux, A., Roupret,
M., Barrou, B., Fehri, K., Lebret,
T., Tostain, J., Terrier, J. E., Terrier,
N., Martin, L., Dugardin, F., Gal-
liot, I., Staerman, F., Azemar, M. D.,
Irani, J., Tisserand, B., Timsit, M.
O., Sallusto, F., Rischmann, P., Guy,
L., Valeri, A., Deruelle, C., Azzouzi,
A. R., Chautard, D., Mejean, A.,
Salomon, L., Rigaud, J., Pﬁster, C.,
Soulié, M., Kleinclauss, F., Badet,
L., Patard, J. J., Comité de Trans-
plantationde l’AssociationFrançaise
d’Urologie, and Comité de Can-
cérologie de l’Association Française
d’Urologie. (2011). Renal cell carci-
noma (RCC) in patients with end
stage renal disease exhibits many
favourable clinical, pathologic, and
outcome features compared with
RCC in the general population. Eur.
Urol. 60, 366–373.
Nouth, M. A., Kuroda, N., Yamashita,
M., Hayashida, Y., Yano, T.,
Minakuchi, J., Taniguchi, S.,
Nomura, I., Inui, M., Sugimoto, M.,
and Kakehi, Y. (2009). Renal cell
carcinoma in patients with end stage
renal disease: relationship between
histological type and duration of
dialysis. BJU Int. 105, 620–627.
Nuttail,M.,Cathcart, van derMeulen, J.,
Gillatt,D.,McIntosh,G., andEmber-
ton,M. (2005). A description of rad-
ical nephrectomy practice and out-
comes in England: 1995-2002. BJU
Int. 96, 58–61.
Ritz, E., and McClellan, W. W. (2004).
Overview: increased cardiovascular
risk in patientswithminor renal dys-
function: an emerging issuewith far-
reaching consequences. J. Am. Soc.
Nephrol. 15, 513–516.
Russo, P. (2000). Renal cell carcinoma:
presentation, staging, and surgi-
cal treatment. Semin. Oncol. 27,
160–176.
Russo,P. (2006).“Open radical nephrec-
tomy for localized renal cell car-
cinoma,” in Genitourinary Oncol-
ogy, 3rd Edn, ed. N. J. Vogelzang
(Philadelphia: Lippincott Williams
and Wilkins), 725–731.
Russo, P. (2010). Partial nephrectomy
for renal cancer (I). BJU Int. 105,
1206–1220.
Russo, P. (2011). The role of surgery in
the management of early-stage renal
cancer. Hematol. Oncol. Clin. North
Am. 25, 737–752.
Russo, P., Jang, T., Eggener, S., Pet-
tus, J., Karellas, M., and O’Brien, F.
(2008). Survival rates after resection
for localized kidney cancer 1989-
2004. Cancer 113, 84–96.
Sarnak,M., Levey,A. S., Schoolwerth,A.
C., Coresh, J., Culleton, B., Hamm,
L. L., McCullough, P. A., Kasiske, B.
L., Kelepouris, E., Klag, M. J., Par-
frey, P., Pfeffer, M., Raij, L., Spin-
osa, D. J., and Wilson, P. W. (2003).
Kidney disease as a risk factor for
the development of cardiovascu-
lar disease: a statement from the
American Heart Association Coun-
cil on Kidney in Cardiovascular Dis-
ease. High blood pressure research,
clinical cardiology, and epidemiol-
ogy and prevention. Circulation 108,
2154–2169.
Segev, D. L., Muzaale, A. D., Caffo,
B. S., Mehta, S. H., Singer, A. L.,
Taranto, S. E., McBride, M. A., and
Montgomery, R. A. (2010). Peri-
operative mortality and long-term
survival following live kidney dona-
tion. JAMA 503, 959–966.
Shlipak, M. G., Fried, L. F., Cushman,
M., Manolio, T. A., Peterson, D.,
Stehman-Breen, C., Bleyer, A., New-
man, A., Siscovick, D., and Psaty,
B. (2005). Cardiovascular mortality
risk in chronic kidney disease: com-
parison of traditional and novel risk
factors. JAMA 293, 1737–1745.
Stengel, B. (2010). Chronic kidney dis-
ease and cancer: a troubling connec-
tion. J. Nephrol. 23, 253–262.
Stenvinkel, P. (2010). Chronic kidney
disease: a public health priority
and harbinger of premature cardio-
vascular disease. J. Int. Med. 268,
456–467.
Stevens, L. A., Coresh, J., Green, T., and
Levey, A. S. (2006). Assessing kidney
function – measured and estimated
glomerular ﬁltration rate. N. Engl. J.
Med. 354, 2473–2483.
Stevens, L. A., Li, S., Wang, C., Becker,
B. N., Bomback, A. S., Brown, W.
W., Burrows, N. R., Jurkovitz, C.
T., McFarlane, S. I., Norris, K. C.,
Shilpak, M., Whaley-Cornell, A. T.,
Chen,S.C.,Barkis,G. L., andMcCul-
lough, P. A. (2010). Prevalence of
CKDand comorbid illness in elderly
patients in the United State: results
from the Kidney Early Evaluation
Program (KEEP). Am. J. Kidney Dis.
55 (3 Suppl. 2), S23–S33.
Stewart, J. H., Vajdoc, C. M., van
Leeuwen, M. T., Amin, J., Webster,
A. C., Chapman, J. R., McDonald,
S. P., Grulich, A. E., and McCredie,
M. R. (2009). The pattern of excess
cancer in dialysis and transplanta-
tion. Nephrol. Dial. Transplant. 10,
3225–3231.
Suson, K. D., Sausville, J. E., Sener,
A., and Phelan, M. W. (2011).
Native nephrectomy for renal
cell carcinoma in transplant
recipients. Transplantation 91,
1376–1379.
Teloken, P. E., Thompson,R. H., Tickoo,
S. K., Cronin, A., Savage, C., Reuter,
V. E., and Russo, P. (2009). Prognos-
tic impact of histological subtype in
patientswith surgically treated local-
ized renal cell carcinoma. J. Urol.
182, 2132–2136.
Thompson,H. R.,Boorjian, S.A., Lohse,
C. M., Leibovich, B. C., Kwon, E.
D., Cheville, J. C., and Blute, M.
L. (2008). Radical nephrectomy for
pT1a renal masses may be associated
with decreased overall survival com-
pared topartial nephrectomy. J.Urol.
179, 468–473.
Thompson, H. R., Kaag, M., Vick-
ers, a., Kundu, S., Bernstein, M.,
Lowrance, W., Galvin, D., Dal-
bagni, G., Touijer, K., and Russo, P.
Frontiers in Oncology | Genitourinary Oncology April 2012 | Volume 2 | Article 28 | 6
Russo Renal insufﬁciency and cancer
(2009). Contemporary use of partial
nephrectomy nephrectomy at a ter-
tiary care center in the United States.
J. Urol. 181, 993–997.
Weng, P. H., Hung, K. Y., Huang, H.
L., Chen, J. H., Sung, P. K., and
Huang, K. C. (2011). Cancer spe-
ciﬁc mortality in chronic kidney dis-
ease: longitudinal followupof a large
cohort. Clin. J. Am. Soc. Nephrol. 6,
1121–1128.
Wong, G., Hayen, A., Chapman, J. R.,
Webster, A. C., Want, J. J., Mitchell,
P., and Craig, J. C. (2009). Associ-
ation of CKD and cancer risk in
older people. J. Am. Soc. Nephrol. 20,
1341–1350.
Conﬂict of Interest Statement: The
author declares that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 04 February 2012; paper
pending published: 28 February 2012;
accepted: 10 March 2012; published
online: 02 April 2012.
Citation: Russo P (2012) End stage and
chronic kidney disease: associations with
renal cancer. Front. Oncol. 2:28. doi:
10.3389/fonc.2012.00028
This article was submitted to Frontiers
in Genitourinary Oncology, a specialty of
Frontiers in Oncology.
Copyright © 2012 Russo. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org April 2012 | Volume 2 | Article 28 | 7
